Here are 1-3 brief analogies for MacroGenics (MGNX):

• It's like a specialized 'factory' for advanced antibody drugs, aiming to do for cancer what companies like Genentech or Amgen have done for biologics.
• Think of it as a research powerhouse for next-generation cancer antibodies, similar to how Regeneron develops innovative antibody therapies, but with a strong emphasis on immuno-oncology.
• It's like a smaller, laser-focused version of Bristol-Myers Squibb or Merck, but dedicated exclusively to inventing and commercializing antibody-based treatments for cancer.

• MARGENZA (margetuximab-cmkb): An approved HER2 receptor antagonist, in combination with chemotherapy, for metastatic HER2-positive breast cancer.
• MGC018: An antibody drug conjugate (ADC) targeting solid tumors expressing B7-H3.
• Enoblituzumab: A monoclonal antibody that targets B7-H3 for cancer treatment.
• MGD024: An investigational bispecific CD123 × CD3 DART molecule for hematologic malignancies.
• Lorigerlimab: A monoclonal antibody targeting the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
• Tebotelimab: An investigational tetravalent DART molecule targeting PD-1 and lymphocyte-activation gene 3 (LAG-3).
• Retifanlimab: An investigational monoclonal antibody for metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer.
• IMGC936: An antibody drug conjugate (ADC) that targets ADAM9, a cell surface protein over-expressed in various solid tumor types.
• MGD014 and MGD020: DART molecules developed to target human immunodeficiency virus (HIV) infected cells and CD3 on T cells.
• Teplizumab: A therapeutic product under development for the treatment of type 1 diabetes.
• PRV-3279: A CD32B × CD79B DART molecule for the treatment of autoimmune indications.

MacroGenics (MGNX) sells primarily to other companies within the pharmaceutical and healthcare ecosystem.

Its major collaborators, which often involve licensing agreements, co-development, or co-commercialization deals that constitute significant business relationships and revenue streams, include:

• Incyte Corporation (INCY)
• Zai Lab Limited (ZLAB)
• I-Mab Biopharma (IMAB)
• Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson (JNJ))

Additionally, for its approved product MARGENZA, MacroGenics' direct customers include pharmaceutical distributors, hospitals, and oncology clinics, which are also "other companies" in the healthcare supply chain that purchase the drug for dispensing to patients.

Eric Risser, President, Chief Executive Officer, and Director

Eric Risser was appointed President and Chief Executive Officer of MacroGenics in August 2025, having previously served as Chief Operating Officer since 2022. He joined the company in 2009 and has been instrumental in leading its corporate development efforts, which have generated over $1.6 billion in non-dilutive capital. Prior to joining MacroGenics, Mr. Risser held the position of Senior Director, Business Development in the pharmaceutical group at Johnson & Johnson from 2003 to 2009. Before his tenure at Johnson & Johnson, he established and developed a consulting practice that advised emerging life science companies in the United States and Europe. Early in his career, Mr. Risser gained experience in venture capital and investment banking at BA Venture Partners and Lehman Brothers Holdings Inc., respectively. He holds an M.B.A. from Stanford University and a B.A. from Yale University.

James Karrels, Senior Vice President, Chief Financial Officer, and Secretary

James Karrels joined MacroGenics in May 2008 as Senior Vice President, Chief Financial Officer, and Corporate Secretary, bringing over 25 years of finance experience, much of which has been in the life sciences sector. Before MacroGenics, he was the Executive Director of Finance at Jazz Pharmaceuticals, Inc. from 2005 to 2008, where he managed financial planning, analysis, and investor relations activities. Mr. Karrels played a key role in the team that facilitated Jazz Pharmaceuticals' initial public offering in 2007. From 1989 to 2002, he was a Director in the Global Healthcare Investment Banking Group at Merrill Lynch, where he accumulated extensive experience in healthcare industry transactions, including IPOs, equity and debt financings, and mergers and acquisitions, participating in over 30 transactions totaling more than $25 billion. He earned his M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.

Ezio Bonvini, M.D., Senior Vice President, Research and Chief Scientific Officer

Dr. Ezio Bonvini is the Senior Vice President, Research and Chief Scientific Officer at MacroGenics, a role he has held since joining the company in June 2003. He is also a co-founder of MacroGenics, established in 2000. Prior to his time at MacroGenics, Dr. Bonvini spent 18 years at the U.S. Food and Drug Administration (FDA) in the Center for Biologics Evaluation and Research (CBER), ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies, and Chief, Laboratory of Immunobiology. Dr. Bonvini received his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.

Frank Perabo, M.D., Ph.D., F.E.B.U., Vice President, Interim Head of Clinical Development

Dr. Frank Perabo joined MacroGenics in July 2025 as Vice President, Interim Head of Clinical Development. He brings over 20 years of global leadership experience within the biopharmaceutical industry, with expertise spanning discovery through late-stage development and commercialization. Dr. Perabo completed his surgical training at the Technical University of Munich and the University of Freiburg and is board-certified in urology from Bonn University, in addition to being a Fellow of the European Board of Urology (F.E.B.U.). He holds an M.D. and Ph.D. from the University of Essen and a degree in cancer biology from the University of Marburg.

Tom Spitznagel, Senior Vice President, Technical Operations

Tom Spitznagel serves as the Senior Vice President, Technical Operations at MacroGenics. Before joining MacroGenics, he was at Human Genome Sciences, where he most recently held the position of Vice President of BioPharmaceutical Development, overseeing Analytical Development, Formulation and Drug Delivery, Purification Sciences, and Fermentation and Cell Culture Sciences. Earlier in his career, Dr. Spitznagel was a Senior Scientist at Nabi from 1996 to 1998 and a Staff Engineer at Genetics Institute from 1992 to 1996. He earned his B.S. in Chemical Engineering from M.I.T. and his Ph.D. in Chemical Engineering from the University of California, Berkeley.

The key risks for MacroGenics (MGNX) primarily revolve around the inherent challenges of the biopharmaceutical industry, particularly concerning drug development, regulatory approvals, and market competition.

1. Clinical Trial and Regulatory Success of Pipeline Products: MacroGenics' future success heavily relies on its extensive pipeline of investigational immuno-oncology product candidates. Biopharmaceutical drug development is a complex, costly, and lengthy process with a high failure rate. There is a significant risk that any of its numerous product candidates, such as MGC018, Enoblituzumab, MGD024, Lorigerlimab, Tebotelimab, Retifanlimab, IMGC936, MGD014, MGD020, Teplizumab, and PRV-3279, may not demonstrate sufficient efficacy or safety in clinical trials, fail to meet regulatory approval criteria, or face unexpected delays in development. The failure of a significant pipeline candidate could severely impact the company's long-term prospects.

2. Commercialization and Market Adoption Challenges: While MacroGenics has an approved product, MARGENZA (margetuximab-cmkb), the successful commercialization of this product and any future approved pipeline candidates is critical. Risks include intense market competition, difficulties in achieving broad physician and patient adoption, pricing pressures, and challenges in securing favorable reimbursement policies from payers. If MARGENZA or future products do not achieve anticipated market penetration or sales volumes, the company's revenue and profitability could be adversely affected.

3. Intense Competition: The biopharmaceutical industry, particularly in the immuno-oncology and cancer treatment space, is highly competitive. MacroGenics faces competition from large pharmaceutical companies and other biotechnology firms that may have greater financial resources, more extensive research and development capabilities, and more established marketing and sales infrastructure. Competitors may develop new drugs that are more effective, safer, or more affordable than MacroGenics' current or future products, potentially eroding market share or rendering its treatments less competitive.

MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing antibody-based therapeutics, primarily for cancer and autoimmune diseases. The addressable markets for their main products and pipeline candidates are substantial:

• MARGENZA (margetuximab-cmkb) for metastatic HER2-positive breast cancer: The market for metastatic HER2-positive breast cancer in the 7 major markets (7MM) was estimated at approximately USD 2,711.6 million in 2024 and is projected to reach USD 3,108.1 million by 2035. In the United States alone, the HER2-positive breast cancer market was valued at over USD 1,600 million in 2023.

• MGC018 and Enoblituzumab targeting B7-H3 for solid tumors and hematologic malignancies: The global market for B7-H3 targeted therapies was valued at USD 484 million in 2024 and is projected to grow to USD 3.4 billion by 2033.

• MGD024 for hematologic malignancies: The global hematologic malignancies market was valued at USD 65.1 billion in 2024 and is expected to reach USD 129.5 billion by 2033. Other estimates place the global market at USD 72.87 billion in 2024, projected to reach USD 147.38 billion by 2033. North America held the largest share of this market, accounting for 41% in 2024.

• Retifanlimab for metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer:

  • Metastatic squamous cell carcinoma of the anal canal (SCAC): The global anal cancer market was valued at USD 928.91 million in 2024 and is projected to reach USD 1,444.76 million by 2033. Squamous cell carcinoma accounts for the majority of anal cancer cases, leading the market with a 61.2% revenue share in 2025. The U.S. anal cancer market alone was valued at USD 0.43 billion in 2024 and is expected to reach USD 0.75 billion by 2032.

  • Metastatic non-small cell lung cancer (NSCLC): The global non-small cell lung cancer market was estimated at USD 20.2 billion in 2024 and is expected to grow to USD 53.9 billion by 2034. The NSCLC market in the 7 major markets (7MM) is projected to reach approximately USD 65 billion by 2034. The U.S. non-small cell lung cancer market was valued at USD 8.2 billion in 2024.

• Teplizumab for type 1 diabetes: The global type 1 diabetes market was estimated at USD 37.60 billion in 2025 and is predicted to grow to approximately USD 79.14 billion by 2035. North America held the largest revenue share in the global Type 1 diabetes market in 2024, accounting for 45.7%.

• PRV-3279 for autoimmune indications: The global autoimmune diseases treatment market was recorded at USD 109.53 billion by the end of 2025 and is projected to reach USD 132.964 billion by 2033. The U.S. autoimmune disease drug market was USD 83.6 billion in 2023 and is expected to reach USD 112.7 billion in 2032.

Here are the expected drivers of future revenue growth for MacroGenics (MGNX) over the next 2-3 years:

1. Advancement and Potential Commercialization of Antibody-Drug Conjugate (ADC) Pipeline: MacroGenics is heavily focused on its innovative ADC pipeline, with several candidates expected to reach significant milestones. Initial Phase 1 clinical data for MGC026 (B7-H3 ADC) is anticipated in mid-2026, and for MGC028 (ADAM9 ADC) in the second half of 2026. Additionally, an Investigational New Drug (IND) submission for MGC030, a first-in-class TOP1i-based ADC, is targeted for the third quarter of 2026. Positive clinical trial results and subsequent progression of these programs could lead to future revenue through development milestones, partnerships, and eventual commercialization.
2. Realization of Milestone Payments from Strategic Collaborations: MacroGenics has established collaborations with industry partners, which represent significant potential for non-dilutive funding and revenue. The company has potential future milestone payments of up to $1.6 billion from Gilead related to ADC and bispecific programs, up to $330 million from Sanofi tied to TZIELD (teplizumab-mzwv) for type 1 diabetes, and up to $540 million from Incyte connected to ZYNYZ (retifanlimab-dlwr), which recently received expanded indications. The achievement of clinical, regulatory, or commercial milestones for these partnered programs will directly contribute to revenue.
3. Growth in Contract Manufacturing Revenue: MacroGenics experienced a strong uplift in contract manufacturing revenue in 2025, which contributed significantly to its total revenue. Continued growth in this area could provide a steady revenue stream independent of product sales.
4. Progression of Bispecific Antibody Programs: Beyond ADCs, MacroGenics is advancing other bispecific molecules, including lorigerlimab (PD-1 x CTLA-4 bispecific DART molecule). A Phase 2 LINNET study update for lorigerlimab is projected for mid-2026, pending the resolution of a partial FDA clinical hold. Positive updates and further advancement of this and other bispecific programs, such as MGD024, could open avenues for future revenue generation.

Share Issuance

• Shares of common stock outstanding increased from approximately 63.09 million on March 14, 2025, to 63.32 million as of December 31, 2025.
• In May 2025, shareholders approved an amendment to the 2023 Equity Incentive Plan, increasing the number of shares available for issuance by 1,250,000 shares.

Inbound Investments

• MacroGenics secured over $600 million in non-dilutive capital from partnerships within the last 3.5 years.
• In 2025, the company received $25 million from Gilead for licensing an additional preclinical program and $50 million from Sanofi for milestone payments related to TZIELD approvals in the UK and China.
• MacroGenics is eligible to receive substantial future milestone payments, including up to $1.6 billion from Gilead programs, up to $540 million from Incyte related to ZYNYZ, and up to $330 million from Sanofi for TZIELD.

Capital Expenditures

• Capital expenditures for the last 12 months (reflecting 2025 data) were reported as -$1.91 million.
• Research and development expenses, a primary area of investment for the biopharmaceutical company, decreased to $147.2 million in 2025 from $177.2 million in 2024.
• The focus of R&D expenditures in 2025 included increased clinical trial costs for MGC026 and MGC028, and development costs for MGC030.